Table 3.
In adenocarcinoma PD-L1 expression in TC was found in both early NSCLC (UICC stage I/II) and advanced NSCLC (UICC stage III/IV). Significant associations were found for KRAS, TP53 and STK11 mutations in univariate regression analysis (depicted) and in multivariate analysis (Fig. 4). All other investigated parameters did not show significant associations (Tables S1, 2).
| PD-L1 expression (Tumor cells) | ||||||
|---|---|---|---|---|---|---|
| No. of patients (NSCLC-Adeno) |
positive |
negative |
Odds ratio |
95% CI |
p-value |
|
| Patient number | 256 | 88 | 168 | |||
| UICC Stage | ||||||
| I / II | 155 | 50 | 105 | |||
| III / IV | 101 | 38 | 63 | 0.377 | ||
| KRAS status | ||||||
| wild-type | 68 | 15 | 53 | |||
| mutated | 55 | 23 | 32 | 2.5 | 1.2–5.6 | 0.018 |
| TP53 status | ||||||
| wild-type | 66 | 15 | 51 | |||
| mutated | 56 | 23 | 33 | 2.4 | 1.1–5.2 | 0.029 |
| STK11 status | ||||||
| wild-type | 97 | 34 | 63 | |||
| mutated | 23 | 2 | 21 | 0.2 | 0.0–0.8 | 0.013 |